The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2020 | The evolving role of IMiDs
Xavier Leleu, MD, PhD, Poitiers University Hospital, Poitiers, France, discusses the importance of immunomodulatory imide drugs (IMiDs) in multiple myeloma treatment. Offsprings of thalidomide, such as lenalidomide and pomalidomide, are very effective treatments for transplant and non-transplant eligible patients. Lenalidomide is one of the best foundations for drug combinations; however, there are still areas for improvement. Some patients treated with lenalidomide become refractory. Dr Leleu also discusses mezigdomide (CC-92480) and iberdomide. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
